[1]王 燕a,胡秀娟a,张 丽a,等.溃疡性结肠炎患者血清Elabela，LRG1水平表达与疾病活动指数的相关性研究[J].现代检验医学杂志,2024,39(01):100-105.[doi:10.3969/j.issn.1671-7414.2024.01.018]
　WANG Yana,HU Xiujuana,ZHANG Lia,et al.Correlation between the Expression of Serum Elabela, LRG1 Levels and Disease Activity Index in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2024,39(01):100-105.[doi:10.3969/j.issn.1671-7414.2024.01.018]
点击复制

溃疡性结肠炎患者血清Elabela，LRG1水平表达与疾病活动指数的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年01期
页码:
100-105
栏目:
论著
出版日期:
2024-01-15

文章信息/Info

Title:
Correlation between the Expression of Serum Elabela, LRG1 Levels and Disease Activity Index in Patients with Ulcerative Colitis
文章编号:
1671-7414（2024）01-100-06
作者:
王 燕a; 胡秀娟a; 张 丽a; 吕竹洁a; 王 龙b; 仝高成b
（运城市中心医院 a. 消化内科；b. 消化内镜室，山西运城044000）
Author(s):
WANG Yana;  HU Xiujuana;  ZHANG Lia;  L? Zhujiea;  WANG Longb;  TONG Gaochengb
（a. Department of Gastroenterology; b. Digestive Endoscopy Room, Yuncheng Central Hospital, Shanxi Yuncheng 044000, China）
关键词:
溃疡性结肠炎; 富亮氨酸α-2 糖蛋白-1; 疾病活动指数; 黏膜愈合
分类号:
R574.62；R446
DOI:
10.3969/j.issn.1671-7414.2024.01.018
文献标志码:
A
摘要:
目的　探讨溃疡性结肠炎（ulcerative colitis，UC）患者血清Elabela，富亮氨酸α?2 糖蛋白-1（leucine-richalpha-2-glycoprotein-1，LRG1）表达及与疾病活动指数（disease activity index, DAI）的相关性。方法　选择2022年1月～2022年12 月运城市中心医院收治的98 例UC 患者为UC 组，其中活动期62 例，缓解期36 例。根据患者病情严重程度分为轻度组（n=26）、中度组（n=43）和重度组（n=29）。根据内镜活动指数（endoscopic activity index，EAI）分为Ⅰ级组（n=25）、Ⅱ级组（n=40）和Ⅲ级组（n=33）。根据内镜下黏膜愈合情况分为愈合组（n=65）和未愈合组（n=33）。另取51 例结肠息肉患者为对照组1，50 例健康体检者为对照组2。采用酶联免疫吸附法检测血清Elabela 和LRG1 水平。Pearson 法分析UC 患者血清Elabela，LRG1 水平与疾病活动指数的相关性。受试者工作特征(ROC) 曲线分析血清Elabela 和LRG1 对内镜下黏膜愈合的预测价值。结果　UC 组血清Elabela（4.77 ± 1.36 ng/ml），LRG1（352.12 ±39.45 ng/ml）水平高于对照组1（2.51 ± 0.53 ng/ml，121.02 ± 21.06 ng/ml）和对照组2（2.35 ± 0.42 ng/ml，120.35± 23.49 ng/ml），差异具有统计学意义（t=11.410 ～ 39.000，均P ＜ 0.05）。活动期组血清Elabela（5.26 ± 0.54 ng/ml），LRG1（370.42 ± 12.49 ng/ml）高于缓解期组（3.93 ± 0.42 ng/ml，320.60 ± 8.47 ng/ml），差异具有统计学意义（t=12.705，21.242，均P ＜ 0.05）。重度组血清Elabela（5.89 ± 0.20 ng/ml），LRG1（369.92 ± 16.59 ng/ml）高于中度组（4.51 ± 0.67 ng/ml，356.12 ± 18.75 ng/ml）和轻度组（3.95 ± 0.21 ng/ml，325.65 ± 10.14 ng/ml），差异具有统计学意义（t=3.205 ～ 35.077，均P ＜ 0.05）。Ⅲ级组血清Elabela（5.80 ± 0.18 ng/ml），LRG1（369.16 ± 13.47 ng/ml）高于Ⅱ级组（4.49 ± 0.35 ng/ml，355.46 ± 16.34 ng/ml）和Ⅰ级组（3.86 ± 0.16 ng/ml，324.15 ± 8.71 ng/ml），差异具有统计学意义（t=3.854 ～ 48.725，均P ＜ 0.05）。未愈合组血清Elabela（5.12 ± 0.42 ng/ml），LRG1（367.12 ±14.27 ng/ml）高于愈合组（4.08 ± 0.37 ng/ml，322.57 ± 10.35 ng/ml），差异具有统计学意义（t=12.043，15.917，均P＜ 0.05）。UC 患者血清Elabela，LRG1 水平与EAI，红细胞沉降率呈正相关（r=0.602，0.298；0.576，0.302，均P ＜ 0.05），与血红蛋白水平呈负相关（r=-0.351，-0.334，均P ＜ 0.05）。血清Elabela，LRG1 联合预测内镜下黏膜愈合的曲线下面积为0.926（95%CI：0.880 ～ 0.958），高于Elabela，LRG1 单独预测的0.803（95%CI：0.741 ～ 0.856），0.783（95%CI：0.720 ～ 0.838）, 差异有统计学意义（Z=4.101，4.228，均P ＜ 0.05）。结论　UC 患者血清Elabela，LRG1 水平升高，且与疾病活动指数增加和病情加重有关，检测血清Elabela，LRG1 可为UC 内镜下黏膜愈合评估提供参考。
Abstract:
Objective　To investigate the expression of serum Elabela and leucine?rich-alpha-2-glycoprotein-1 (LRG1) in ulcerative colitis (UC) patients and their correlation with disease activity index (DAI). Methods　A total of 98 patients with UC admitted to Yuncheng Central Hospital from January to December 2022 were selected as the UC group, including 62 patients in active stage and 36 patients in remission stage. According to the severity of the disease, these patients were divided into mild group (n=26), moderate group (n=43) and severe group (n=29). In addition, these patients were grouped into grade Ⅰ group (n=25), grade Ⅱ group (n=40) and grade Ⅲ group (n=33) based on the endoscopic activity index (EAI). According to the mucosal healing condition under endoscopy, these patients were divided into the healed group (n=65) and the unhealed group (n=33). Another 51 patients with colonic polyps were selected as control group 1, and 50 healthy individuals were selected as control group 2. Serum Elabela and LRG1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Pearson method was used to analyze the correlation between serum Elabela, LRG1 levels and DAI in UC patients. Receiver operating characteristic (ROC) curve was applied to analyze the predictive value of serum Elabela and LRG1 for endoscopic mucosal healing. Results　The levels of Elabela (4.77 ± 1.36 ng/ml) and LRG1 (352.12 ± 39.45 ng/ml) in UC group were higher than those in control group 1 (2.51 ± 0.53 ng/ml, 121.02 ± 21.06 ng/ml) and control group 2 (2.35 ± 0.42 ng/ml, 120.35 ± 23.49 ng/ml), and the differences were statistically significant (t= 11.410 ～ 39.000, all P < 0.05). The levels of Elabela (5.26 ± 0.54 ng/ml) and LRG1 (370.42 ± 12.49 ng/ml) in the active group were higher than those in the remission group (3.93 ± 0.42 ng/ml, 320.60 ± 8.47 ng/ml), and the differences were statistically significant (t=12.705, 21.242, all P < 0.05). The levels of Elabela (5.89 ± 0.20 ng/ml) and LRG1 (369.92 ± 16.59 ng/ml) in the severe group were higher than those in the moderate groups (4.51 ± 0.67 ng/ml, 356.12 ± 18.75 ng/ml) and mild groups (3.95 ± 0.21 ng/ml, 325.65 ± 10.14 ng/ml), and the differences were statistically significant (t=3.205 ～ 35.077, all P<0.05). The levels of Elabela (5.80 ± 0.18 ng/ml) and LRG1 (369.16 ± 13.47 ng/ml) in grade Ⅲ group were higher than those in grade Ⅱ group (4.49 ± 0.35 ng/ml, 355.46 ± 16.34 ng/ml) and grade Ⅰ group (3.86 ± 0.16 ng/ml, 324.15 ± 8.71 ng/ml), and the differences were statistically significant (t= 3.854 ～ 48.725, all P < 0.05). The levels of Elabela (5.12 ± 0.42 ng/ml) and LRG1 (367.12 ± 14.27 ng/ml) in unhealed group were higher than those in healed group (4.08 ± 0.37 ng/ml, 322.57 ± 10.35 ng/ml), and the differences were statistically significant (t=12.043, 15.917, all P < 0.05). The serum levels of Elabela and LRG1 in UC patients were positively correlated with EAI and ESR (r=0.602, 0.298; 0.576, 0.302, all P < 0.05), but negatively correlated with hemoglobin level (r=-0.351, -0.334, all P < 0.05). The area under the curve predicted by the combination of serum Elabela and LRG1 for endoscopic mucosal healing was 0.926 (95% CI: 0.880 ～ 0.958), was higher than the 0.803 (95% CI: 0.741 ～ 0.856) and 0.783 (95% CI: 0.720 ～ 0.838) predicted by Elabela and LRG1 alone, and the difference was statistically significant(Z=4.101, 4.228, all P<0.05). Conclusion　The serum levels of Elabela and LRG1 in UC patients increased, and they were related to the increase of DAI and worsening of the condition. Testing serum Elabela and LRG1 can provide a reference for evaluating mucosal healing under UC endoscopy.

参考文献/References:

[1] MARINELLI C, ZINGONE F, LUPO M G, t al. Serum levels of PCSK9 are increased in patients with active ulcerative colitis representing a potential biomarker of disease activity: a cross-sectional study[J]. Journal of Clinical Gastroenterology, 2022, 56(9): 787-793.
[2] 杨思贤, 慕奕彤, 牛福玉．粪便S100A12, 钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析[J]. 现代检验医学杂志, 2022, 37(3)：172-176． YANG Sixian, MU Yitong, NIU Fuyu. Evaluation value of stool S100a12, fecal calprotectin and lactoferrin for disease activity and mucosal healing in patients with ulcerative colitis [J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 172-176.
[3] SONG Juanjuan, YANG Mei, LIU Ying, et al. Elabela prevents angiotensin II-induced apoptosis and inflammation in rat aortic adventitial fibroblasts via the activation of FGF21-ACE2 signaling[J]. Journal of Molecular Histology, 2021, 52(5): 905-918.
[4] CAMILLI C, HOEH A E, DE ROSSI G, et al. LRG1: an emerging player in disease pathogenesis[J]. Journal of Biomedical Science, 2022, 29(1): 6.
[5] LIU Jianjun, PEK S L T, WANG Jiexun, et al. Association of plasma leucine-rich α-2 glycoprotein 1, a modulator of transforming growth factor-β signaling pathway, with incident heart failure in individuals with type 2 diabetes[J]. Diabetes Care, 2021, 44(2): 571-577.
[6] 中华中医药学会．溃疡性结肠炎诊疗指南[J]．中国中医药现代远程教育, 2011, 9(10)：126-128． China Association of Chinese Medicine. Guidelines for diagnosis and treatment of ulcerative colitis[J]. Chinese Medicine Modern Distance Education of China, 2011, 9(10): 126-128.
[7] KIM K O. Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice[J]. Clinical Endoscopy, 2022, 55(4): 480-488.
[8] 陈霞飞, 孙琦, 张晓琦, 等．溃疡性结肠炎内镜评分与临床活动度及组织学评分的相关性研究[J]. 中华消化内镜杂志, 2021, 38(6)：447-453． CHEN Xiafei, SUN Qi, ZHANG Xiaoqi, et al. Correlation between endoscopic scores and clinical activity and histological scores of ulcerative colitis [J].Chinese Journal of Digestive Endoscopy, 2021, 38(6): 447-453.
[9] ZHANG Chong, CHEN Honglü, HE Qiaoling, et al. Fibrinogen/AKT/microfilament axis promotes colitis by enhancing vascular permeability[J]. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11(3): 683-696.
[10] CHEN Shengbo, LIU Hongbin, LI Zhijun, et al. Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling[J]. Cell Death & Disease, 2021, 12(6): 563.
[11] MATSUMOTO K, YAMABA R, INOUE K, et al. Transient receptor potential vanilloid 4 channel regulates vascular endothelial permeability during colonic inflammation in dextran sulphate sodiuminduced murine colitis[J]. British Jornal of Pharmacology, 2018, 175(1): 84-99.
[12] ZHENG Qian, TIAN Geng, XU Feng, et al. The role of Elabela in kidney disease[J]. International Urology and Nephrology, 2021, 53(9): 1851-1857.
[13] ZHANG Zhenzhou, TANG Jianqiong, SONG Jiawei, et al. Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling [J]. Free Radical Biology & Medicine, 2022, 181: 130-142.
[14] MA Zheng, SONG Juanjuan, MARTIN S, et al. The Elabela-APJ axis: a promising therapeutic target for heart failure[J]. Heart Failure Reviews, 2021, 26(5): 1249-1258.
[15] SUMBUL H E, GULUMSEK E, AVCI B S, et al. Serum elabela level is significantly increased in patients with acromegaly[J]. Irish Journal of Medical Science, 2023, 192(2): 665-670.
[16] JAVAID F, PILOTTI C, CAMILLI C, et al. Leucinerich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target[J]. RSC Chem Biol, 2021, 2(4): 1206-1220.
[17] ZOU Yonghui, XU Yi, CHEN Xiaofeng, et al. Research progress on leucine-rich alpha-2 glycoprotein 1: a review[J]. Frontiers in Pharmacology, 2021, 12: 809225.
[18] KAWAMOTO A, TAKENAKA K, HIBIYA S, et al. Serum leucine-rich α2 glycoprotein: a novel biomarker for small bowel mucosal activity in crohn's disease[J].Clinical Gastroenterology and Hepatology, 2022, 20(5): e1196-e1200.
[19] PANG K T, GHIM M, LIU Chenghao, et al. Leucinerich α-2-glycoprotein 1 suppresses endothelial cell activation through Adam10-mediated shedding of TNF-α receptor[J]. Frontiers in Cell and developmental Biology, 2021, 9: 706143.
[20] 霞明, 朱杰伦, 陈娟, 等．溃疡性结肠炎患者结肠黏膜组织中LRG1, TGF-β 和Smad2 表达水平及临床意义[J]．临床和实验医学杂志, 2018, 17(11)：1149-1153． XIA Ming, ZHU Jielun, CHEN Juan, et al. The expression levels and clinical significances of LRG1,TGF-β and Smad2 in the colonic mucosa tissues of patients with ulcerative colitis [J]. Journal of Clinical and Experimental Medicine, 2018, 17(11): 1149-1153.

相似文献/References:

[1]杨思贤,慕奕彤,牛福玉.粪便S100A12，钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析[J].现代检验医学杂志,2022,37(03):172.[doi:10.3969/j.issn.1671-7414.2022.03.036]
　YANG Si-xian,MU Yi-tong,NIU Fu-yu.Evaluation Value of Stool S100A12, Fecal Calprotectin and Lactoferrin for Disease Activity and Mucosal Healing in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2022,37(01):172.[doi:10.3969/j.issn.1671-7414.2022.03.036]
[2]王 飞,祝 靳,赵宝林.溃疡性结肠炎患者血清LncRNA Mirt2 和LncRNA IFNG-AS1 表达水平及与预后相关性研究[J].现代检验医学杂志,2023,38(03):114.[doi:10.3969/j.issn.1671-7414.2023.03.020]
　WANG Fei,ZHU Jin,ZHAO Bao-lin.Study on the Expression Levels of Serum LncRNA Mirt2 and LncRNA IFNGAS1 in Patients with Ulcerative Colitis and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2023,38(01):114.[doi:10.3969/j.issn.1671-7414.2023.03.020]
[3]关李稳,刘真义,周真真,等.溃疡性结肠炎患者血清LncRNA TUG1 和miR-142-5p 表达与疾病活动度及预后的关系[J].现代检验医学杂志,2023,38(05):70.[doi:10.3969/j.issn.1671-7414.2023.05.013]
　GUAN Liwen,LIU Zhenyi,ZHOU Zhenzhen,et al.Relationship between Serum LncRNA TUG1 and miR-142-5p Expression and Disease Activity and Prognosis in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2023,38(01):70.[doi:10.3969/j.issn.1671-7414.2023.05.013]
[4]沈丹丹,王 鸿.溃疡性结肠炎活动期患者血清TRIM22 和KLF2 水平与病情及临床结局的关系[J].现代检验医学杂志,2024,39(04):143.[doi:10.3969/j.issn.1671-7414.2024.04.026]
　SHEN Dandan,WANG Hong.Relationship among Serum TRIM22 and KLF2 Levels, Disease Condition and Clinical Outcome of Patients with Active Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2024,39(01):143.[doi:10.3969/j.issn.1671-7414.2024.04.026]

备注/Memo

备注/Memo:
基金项目：山西省卫生健康科研课题（2019066）：溃疡性结肠炎患者50KDa 的糖蛋白水平变化与疾病活动指数的相关性研究。
作者简介：王燕（1982-），女，硕士，主治医师，研究方向：炎症性肠病，E-mail：wina7335831@163.com。
更新日期/Last Update: 2024-01-15